For NSCLC patients with EGFR sensitive mutation, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been used clinically as the first-line treatment [2–4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.